Erectile dysfunction that isn't just vascular — the desire and arousal complexity
9 min read · Uplevel editorial
The pill works. Mechanically, it works. You take it an hour before, the plumbing performs, the encounter happens. And yet something is off in a way that's hard to name and harder to bring up — with your partner, with your doctor, or even with yourself. The desire isn't quite there. The anticipation is muted. Arousal takes longer to build and feels less urgent when it arrives. The connection you used to feel, the charged quality of attraction, has been replaced by something that feels more like going through motions than genuine want. You look at your partner and the feeling isn't absent, but it's quieter. The morning erections that used to be reliable and almost annoying are now intermittent, sometimes absent. The PDE5 inhibitor handles the mechanics. It can't manufacture desire. It can't restore the arousal that's supposed to precede and create the conditions for physical response. You are, in an important sense, medicating around a problem without addressing it.
The conventional ED workup is oriented toward the vascular picture, and not without reason — endothelial dysfunction and impaired penile blood flow are the most common identifiable mechanism in men with erectile dysfunction, and PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are genuinely effective for vascular ED, evidence-based, and reasonably safe. The workup typically screens for cardiovascular risk factors, checks fasting glucose and hemoglobin A1c for diabetes, and may include testosterone. This is appropriate as a starting point. But it is not the full picture, and for men whose experience of the problem is more "desire is gone" than "the erection failed," the vascular framework misses something important.
Erection is not simply a hydraulic event. It is the end product of a cascade that begins in the brain. The desire phase is neurochemical — dopaminergic pathways in the mesolimbic system generate wanting, anticipation, and the motivational charge that initiates sexual behavior. The arousal phase involves the integration of sensory input, cognitive context, and emotional state into a centrally generated signal that travels down through the spinal cord and activates the peripheral vascular response. PDE5 inhibitors act at the very end of this cascade, at the vascular level, by preserving the cyclic GMP signal that dilates penile blood vessels in response to nitric oxide. They do nothing upstream. They do not act on dopaminergic desire pathways. They do not modulate the central arousal signal. They do not address the emotional or relational context in which sexual response is embedded. They make the pipes work. They cannot turn the water on.
This matters because erectile dysfunction with absent or muted desire, delayed arousal, and changed morning erection pattern is often telling you something about the upstream picture — not the pipes. Several distinct mechanisms deserve consideration.
Testosterone is the obvious one, and it is genuinely relevant. Testosterone has androgen receptor expression throughout the central nervous system, including in the hypothalamus and limbic structures that govern sexual motivation. Low testosterone reduces libido directly, at the level of desire generation, before any vascular component enters the picture. In men with genuinely low testosterone, treating the hormonal deficit often restores desire in ways that PDE5 inhibitors alone do not. The pattern of symptoms is informative: when the desire is muted alongside the physical dysfunction, testosterone status should be evaluated early and completely — meaning total T, free T, SHBG, LH, FSH, and estradiol in a morning draw.
Prolactin is frequently missed. Elevated prolactin — from a pituitary adenoma, from certain medications (antipsychotics, metoclopramide, some antidepressants), or from hypothyroidism — suppresses GnRH, which drives down LH and testosterone, and also has direct inhibitory effects on sexual desire. A man with elevated prolactin will have a blunted libido and impaired erectile function that traces back to a pituitary or medication issue. A prolactin level belongs in the evaluation of any man with both erectile dysfunction and reduced sexual desire.
The SSRI picture is underappreciated and considerably more common than clinical recognition suggests. SSRIs and SNRIs produce sexual side effects in a substantial proportion of users — estimates range widely, but anorgasmia, ejaculatory delay, and reduced libido are reported frequently enough that they're listed prominently in prescribing information. What's less appreciated is the post-SSRI sexual dysfunction phenomenon: for some men, the sexual side effects do not resolve upon discontinuation of the medication. Desire remains blunted, arousal latency remains long, genital sensation remains diminished. The mechanism is not fully characterized but may involve persistent changes in serotonergic tone and its inhibitory effects on dopaminergic pathways, or epigenetic changes in receptor expression. Men with this history deserve a clinical conversation that addresses the SSRI timeline specifically rather than defaulting to a PDE5 inhibitor as a fix.
The psychological and relational dimensions are real and deserve more than a dismissal as "performance anxiety." The brain's arousal system is context-sensitive. Chronic relationship stress, emotional disconnection from a partner, unresolved conflict, grief, work-related anxiety, or a pattern of sexual experiences that have repeatedly felt unsatisfying can functionally suppress central arousal pathways through stress-hormone mechanisms. Cortisol is antagonistic to sexual arousal — elevated cortisol activates threat-detection circuitry that deprioritizes reproductive behavior. A man in a prolonged stress state may have normal vascular function and adequate testosterone and still experience significant arousal difficulty, because the brain is not generating the upstream signal that the vascular system is waiting for.
Where peptides enter this picture is at the central mechanism level, which is where PDE5 inhibitors do not reach. PT-141, also known as bremelanotide, is a melanocortin receptor agonist that acts centrally to activate desire and arousal pathways — specifically the MC3R and MC4R receptors in the hypothalamus and surrounding structures. It was developed from a compound originally studied as a tanning agent, and in the course of that research, was observed to produce spontaneous and quite robust sexual arousal as a side effect. The mechanism is upstream of everything the PDE5 pathway does. PT-141 does not act on blood vessels. It acts on the brain's arousal circuitry directly, generating the desire signal rather than facilitating the downstream vascular response to a signal that's already present. It has received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women. In men, its use is off-label, but it has been incorporated into some men's health clinical practices and researched for its potential role in men with desire-phase sexual dysfunction or central arousal difficulty. It is not a replacement for a vascular workup. It is a different intervention for a different mechanism.
Kisspeptin-10 represents another upstream avenue, in this case at the hormonal level rather than the direct arousal level. Kisspeptin is a hypothalamic neuropeptide that activates GnRH release — it sits at the top of the HPG axis. Research, including human studies, suggests that kisspeptin has direct limbic effects on sexual brain networks beyond its HPG-stimulating role, and may have a role in mediating the desire dimension of sexual motivation. This research is preliminary. It is not clinical practice in the standard sense. But it represents the kind of upstream, mechanistic thinking about male sexual function that the conventional vascular framework consistently omits.
HCG and testosterone optimization are relevant when the clinical picture includes demonstrable hormonal deficit. In men on TRT for other reasons, sexual function outcomes are often better when testicular function is maintained with HCG alongside testosterone — the reasons are not fully characterized but may involve intratesticular hormones, local neurosteroid production, or simply the psychological and physiological significance of testicular size and function.
None of this diminishes the foundational role of a thorough urological or men's health specialist evaluation. PDE5 inhibitors remain first-line for the common vascular presentation of ED and are appropriate as a starting point. The point is that men whose experience of the problem involves the desire and arousal dimensions — not just the mechanics — deserve a workup and a conversation that reflects the full complexity of how male sexual function actually works. That means testosterone and hormonal evaluation, prolactin, a careful medication history, and a clinical conversation that distinguishes between vascular ED that is well-served by PDE5 inhibitors and central arousal dysfunction that requires a different framework. The experience of wanting sex, anticipating it, and feeling genuinely aroused is not a side issue to erectile mechanics. It is, arguably, the primary thing. And it is the dimension that the current pharmacological standard largely ignores.
The man who is reaching for a pill every time is not a man whose sexual health has been addressed. He is a man whose plumbing has been managed while the upstream question has gone unanswered. That question deserves to be asked.
Frequently asked